Esters-buliding-blocks

Yavuz, Serap Simsek published the artcileAntiviral treatment of COVID-19, Synthetic Route of 55981-09-4, the main research area is review antiviral treatment COVID 19; Covid-19; Sars-CoV-2; antiviral.

Currently, there is not any specific effective antiviral treatment for COVID-19. Although most of the COVID-19 patients have mild or moderate courses, up to 5%-10% can have severe, potentially life threatening course, there is an urgent need for effective drugs. Optimized supportive care remains the mainstay of therapy. Thre have been more than 300 clin. trials going on, various antiviral and immunomodulating agents are in various stages of evaluation for COVID-19 in those trials and some of them will be published in the next couple of months. Despite the urgent need to find an effective antiviral treatment for COVID-19 through randomized controlled studies, certain agents are being used all over the world based on either in-vitro or extrapolated evidence or observational studies. Th most frequently used agents both in Turkey and all over the world including chloroquine, hydroxychloroquine, lopinavir/ ritonavir, favipiravir and remdesivir will be reviewed here. Nitazoxanide and ivermectin were also included in this review as they have recently been reported to have an activity against SARS-CoV-2 in vitro and are licensed for the treatment of some other human infections.

Turkish Journal of Medical Sciences published new progress about COVID-19. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Synthetic Route of 55981-09-4.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Kelleni, Mina T. published the artcileNitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management, SDS of cas: 55981-09-4, the main research area is COVID19 nitazoxanide azithromycin; Azithromycin; COVID-19; Interferons; Nitazoxanide; SARS CoV-2.

Azithromycin has been shown to have a clin. efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable exptl. efficacy with a potential to be used for Coronavirus disease 2019. Further, BCG vaccination is being considered for clin. trials aiming to test its potential for lowering COVID-19 morbidity and mortality. This article illustrates some structural and functional relationships that may gather these drugs and the author, basing on a combined pathophysiol. and pharmacol. approach, recommends the FDA-approved antidiarrhea drug; nitazoxanide, which has been previously suggested but unfortunately widely ignored, to be tested in combination with azithromycin for their potential activity against SARS CoV-2, soonest. The author also recommends testing their combined administration as early during the clin. course of COVID-19 as possible. Further, basing on the same represented concept, the author suggests more trials for interferons to be tested against SARS CoV-2, especially in severe and critical COVID-19 cases.

Pharmacological Research published new progress about COVID-19. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, SDS of cas: 55981-09-4.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Stachulski, Andrew V. published the artcileTherapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?, Formula: C12H9N3O5S, the main research area is review COVID 19 nitazoxanide; COVID-19; SARS-CoV-2; antiviral; coronavirus; nitazoxanide; pharmacokinetics; tizoxanide.

The rapidly growing COVID-19 pandemic is the most serious global health crisis since the Spanish flu of 1918. There is currently no proven effective drug treatment or prophylaxis for this coronavirus infection. While developing safe and effective vaccines is 1 of the key focuses, a number of existing antiviral drugs are being evaluated for their potency and efficiency against SARS-CoV-2 in vitro and in the clinic. We review the significant potential of nitazoxanide (NTZ) as an antiviral agent that can be repurposed as a treatment for COVID-19. Originally, NTZ was developed as an antiparasitic agent especially against Cryptosporidium spp.; it was later shown to possess potent activity against a broad range of both RNA and DNA viruses, including influenza A, hepatitis B and C, and coronaviruses. Recent in vitro assessment of NTZ has confirmed its promising activity against SARS-CoV-2 with an EC50 of 2.12μM. We examine its drug properties, antiviral activity against different viruses, clin. trials outcomes, and mechanisms of antiviral action from the literature to highlight the therapeutic potential for the treatment of COVID-19. Furthermore, in preliminary PK/PD analyses using clin. data reported in the literature, comparison of simulated TIZ (active metabolite of NTZ) exposures at 2 doses with the in vitro potency of NTZ against SARS-CoV-2 gives further support for drug repurposing with potential in combination chemotherapy approaches. The review concludes with details of 2nd generation thiazolides under development that could lead to improved antiviral therapies for future indications.

ACS Infectious Diseases published new progress about COVID-19. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Formula: C12H9N3O5S.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Calderon, Jose Meneses published the artcileNitazoxanide against COVID-19 in three explorative scenarios, Quality Control of 55981-09-4, the main research area is nitazoxanide COVID19 pregnancy; SARS-CoV-2; ambulatory treatment; internal medicine; nitazoxanide; pregnancy.

Introduction: Nitazoxanide has shown efficacy in vitro against coronavirus infections (MERS, SARS, SARS-CoV-2). The aim of this report is to describe the results of treating COVID-19 pos. patients with nitazoxanide in three clin. settings: pregnancy/puerperium, hospitalized patients in an Internal Medicine Service and in an ambulatory setting. Methodol.: This was a prospective follow-up and report of COVID-19 cases in three different situations, pregnant women, hospitalized patients receiving medical attention in an Internal Medicine Service and ambulatory patients residing in Toluca City, and Mexico City. Results: The experience with a first group of 20 women, pregnant (17) or in immediate puerperium (3) was successful in 18 cases with two unfortunate deaths. The five cases treated in an Internal Medicine service showed a pos. outcome with two patients weaned from mech. ventilation. Of the remaining 16 patients treated in an ambulatory setting, all got cured. Nitazoxanide seems to be useful against SARS-CoV-2, not only in an early intervention but also in critical condition as well as in pregnancy without undesired effects for the babies. As an adjunctive therapy budesonide was used that seems to contribute to the clin. improvement. Conclusions: Nitazoxanide could be useful against COVID-19 as a safe and available regimen to be tested in a massive way immediately.

Journal of Infection in Developing Countries published new progress about COVID-19. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Quality Control of 55981-09-4.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Aherfi, Sarah published the artcileDrug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV, Category: esters-buliding-blocks, the main research area is review COVID 19 drug repurposing SARS health; COVID-19; SARS-CoV-1; SARS-CoV-2; antiviral; coronavirus; drug repurposing; in silico; in vitro testing.

Since the beginning of the COVID-19 pandemic, large in silico screening studies and numerous in vitro studies have assessed the antiviral activity of various drugs on SARS-CoV-2. In the context of health emergency, drug repurposing represents the most relevant strategy because of the reduced time for approval by international medicines agencies, the low cost of development and the well-known toxicity profile of such drugs. Herein, we aim to review drugs with in vitro antiviral activity against SARS-CoV-2, combined with mol. docking data and results from preliminary clin. studies. Finally, when considering all these previous findings, as well as the possibility of oral administration, 11 mols. consisting of nelfinavir, favipiravir, azithromycin, clofoctol, clofazimine, ivermectin, nitazoxanide, amodiaquine, heparin, chloroquine and hydroxychloroquine, show an interesting antiviral activity that could be exploited as possible drug candidates for COVID-19 treatment.

Future Microbiology published new progress about COVID-19. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Category: esters-buliding-blocks.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Bishara, Delia published the artcileEmerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents, Category: esters-buliding-blocks, the main research area is human covid19 virus drug interaction psychotropic agent; adverse effects; drug-interactions; psychotropic drugs; treatment COVID-19.

As yet, no agents have been approved for the treatment of COVID-19, although several exptl. drugs are being used off licence. These may have serious adverse effects and potential drug interactions with psychotropic agents. We reviewed the common agents being used across the world for the treatment of COVID-19 and investigated their drug interaction potential with psychotropic agents using several drug interaction databases and resources. A preliminary search identified the following drugs as being used to treat COVID-19 symptoms: atazanavir (ATV), azithromycin (AZI), chloroquine (CLQ)/hydroxychloroquine (HCLQ), dipyridamole, famotidine (FAM), favipiravir, lopinavir/ritonavir (LPV/r), nitazoxanide, remdesivir, ribavirin and tocilizumab. Many serious adverse effects and potential drug interactions with psychotropic agents were identified. The most problematic agents were found to be ATV, AZI, CLQ, HCLQ, FAM and LPV/r in terms of both pharmacokinetic as well as serious pharmacodynamic drug interactions, including QTc prolongation and neutropenia. Significant caution should be exercised if using any of the medications being trialled for the treatment of COVID-19 until robust clin. trial data are available. An even higher threshold of vigilance should be maintained for patients with pre-existing conditions and older adults due to added toxicity and drug interactions, especially with psychotropic agents.

Therapeutic Advances in Psychopharmacology published new progress about COVID-19. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Category: esters-buliding-blocks.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Kaddoura, Malak published the artcileCOVID-19 therapeutic options under investigation, Computed Properties of 55981-09-4, the main research area is review human covid19 virus immunomodulator; COVID-19; SARS-CoV-2; adjunctive therapy; antivirals; therapeutics.

Since its emergence in China in Dec. 2019, COVID-19 has quickly spread around the globe causing a pandemic. Vaccination or the development of herd immunity seems the only way to slow down the spread of the virus; however, both are not achievable in the near future. Therefore, effective treatments to mitigate the burden of this pandemic and reduce mortality rates are urgently needed. Preclin. and clin. studies of potential antiviral and immunomodulatory compounds and mols. to identify safe and efficacious therapeutics for COVID-19 are ongoing. Two compounds, remdesivir, and dexamethasone have been so far shown to reduce COVID-19-associated death. Here, we provide a review of the potential therapeutic agents being considered for the treatment and management of COVID-19 patients.

Frontiers in Pharmacology published new progress about COVID-19. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Computed Properties of 55981-09-4.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Hemmati, Farshad published the artcileMysterious Virus: A Review on Behavior and Treatment Approaches of the Novel Coronavirus, 2019-nCoV, Safety of 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, the main research area is review treatment behavior coronavirus 2019 nCoV; 2019-nCoV; Infection; Novel coronavirus; Respiratory problem; Treatment approach.

At the end of the year 2019, the novel coronavirus (2019-nCoV) was spreading in Wuhan, China, and the outbreak process has a high speed. It was recognized as a pandemic by the World Health Organization (WHO) on 11 March 2020. Coronaviruses are enveloped and single-stranded RNA that have several families including Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). The pathogenesis mechanism and disease outcomes of SARS and MERS are now clear to some extent, but little information is available for 2019-nCoV. This newly identified corona virus infection represents flu-like symptoms, but usually the first symptoms are fever and dry cough. There has been no specific treatment against 2019-nCoV up to now, and physicians only apply supportive therapy. In the present article, we made an attempt to review the behavior of the virus around the world, epidemiol., a pathway for influx into the host cells, clin. presentation, as well as the treatments currently in use and future approaches; nitazoxanide may be our dream drug. We hope that this review has a pos. impact on public knowledge for helping to deal with the 2019-nCoV and move one step forward toward its treatment in the near future.

Archives of Medical Research published new progress about COVID-19. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Safety of 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Cherrez-Ojeda, Ivan published the artcileThe unusual experience of managing a severe COVID-19 case at home: what can we do and where do we go?, Computed Properties of 55981-09-4, the main research area is covid19 pandemic mental disease; Ambulatory care; COVID-19; Developing countries; South America.

Abstract: Background: The speed and reach of the COVID-19 pandemic has created special scenarios to be considered, such as those in where patients who meet criteria for hospitalization due to moderate/severe disease cannot be hospitalized due to economic constraints and saturation of national health systems. The aim of this report is to present an unusual case of a severe COVID-19 patient managed at home in a developing country, and to discuss some of the available guidelines and potential therapeutic options for this type of cases. Case presentation: A 60-yr-old female seeking medical attention through teleconsultation presents with profound dyspnea, oppressive chest pain, fatigue, episodic hallucinations, and difficulty sleeping, for what she originally sought medical attention at an ER but could not be admitted due to saturation of the health system. A pos. PCR test for COVID-19, and a CT scan of the chest showing bilateral consolidations with ground-glass opacities confirmed the diagnosis. The patient was managed at home, with corticosteroids, nitazoxanide and a single dose of 40 mg of s.c. enoxaparin. Colchicine was added at the third day of treatment. Standard oxygen therapy through nasal cannula was also recommended. Daily follow-ups were established to monitor for signs of clin. improvement. Two weeks later from the initial consultation the patient presents marked improvement in her symptoms, as well as in her CT scan, which prompted in discontinuation of the medications and the oxygen therapy. Conclusions: There are several limitations in this report regarding the clin. data and the management, but such limitations do also reflect the state of emergency and the chaos that resides in the health care systems of developing nations. For the ambulatory care of COVID-19 patients, several aspects of disease management may differ from current guidelines and basic requirements may represent a huge challenge to cover. Further research is needed to assist physicians in the daily clin. decision making, to optimize patient outcomes, and to reduce the probability of adverse scenarios of patients with COVID-19 managed in the ambulatory setting.

BMC Infectious Diseases published new progress about COVID-19. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Computed Properties of 55981-09-4.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Nolan, Mark D. published the artcileRadical-mediated thiol-ene ‘Click’ reactions in deep eutectic solvents for bioconjugation, COA of Formula: C10H10O2, the main research area is peptide synthesis deep eutectic solvent bioconjugation thiol ene reaction; glycosylation hydrothiolation radical UV green chem recycling fluorescence.

Herein, we report the first application of deep eutectic solvents (DESs) in radical-mediated hydrothiolation reactions. Under UV and atm.-oxygen mediated conditions, the thiol-ene reaction was applied to amino acid and peptide ligation in DESs. The conditions facilitate highly-efficient synthesis of biomol. targets using a ‘green’ methodol., with complete recycling of the reaction medium. Fluorescent labeling and glycosylation of a minimal sequence mimetic of angiotensin-converting enzyme 2 capable of binding the SARS-CoV-2 spike protein is demonstrated for applications in the study of inhibition of COVID-19 infectivity.

Green Chemistry published new progress about COVID-19. 583-04-0 belongs to class esters-buliding-blocks, name is Allyl benzoate, and the molecular formula is C10H10O2, COA of Formula: C10H10O2.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics